Adam Palmer

25PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursMolecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Sep 02, 2026
Varying Cancer Drug Doses to Balance Tumor Control and Resistance Evolution.

|Jun 15, 2026
Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models.

|Jun 01, 2026
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer.

|Mar 23, 2026
When Survival Improves But Quality of Life Does Not: A Model-Based Meta-Analysis of Immune Checkpoint Inhibitors.

Yimeng Sun, Shiwon Chang, Kayden Tang

|Dec 17, 2025
Cross-resistance of Belinostat and Romidepsin in Non-T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP.

Jacob C Pantazis, Adam C Palmer

|Nov 24, 2025
Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma.

Jacob C Pantazis, Amy E Pomeroy, Adam C Palmer

Pageof 5

Frequent Collaborators

8 joint publications

Deborah Plana

8 joint publications

Amy E Pomeroy

5 joint publications

Peter K Sorger

3 joint publications

Jacob C Pantazis